Targeting IDH3α can improve chemoimmunotherapy outcomes by reversing immunosuppressive conditions, enabling better CD8+ T cell infiltration, TME modulation, and immune signaling reactivation, making IDH3α a potential therapeutic target and biomarker for treatment response in IDH3α-overexpressing cancers (28). Here, CD8A is linked to cancer.